Ms Contin (Morphine Sulfate)

Ms Contin is an opioid analgesic indicated for pain conditions that require strong, sustained relief.

• Moderate to severe acute pain: provides rapid analgesia for postoperative or trauma‑related pain.
• Chronic cancer pain: maintains long‑term pain control in patients with malignant disease.
• Severe chronic non‑cancer pain: offers sustained relief for conditions such as neuropathic or musculoskeletal pain unresponsive to other therapies.

• Morphine sulfate acts as a full agonist at mu‑opioid receptors in the central nervous system. Activation of these receptors inhibits the release of neurotransmitters involved in pain transmission, reduces neuronal excitability, and alters the perception of pain, resulting in effective analgesia.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset occurring shortly after dosing.
• Constipation: reduced bowel motility, often requiring prophylactic laxatives.
• Drowsiness or sedation: mild central nervous system depression.
• Dry mouth: decreased salivation leading to discomfort.
• Pruritus: mild itching, especially with higher doses.
• Miosis: pinpoint pupils as a pharmacologic sign.

Serious or Rare Side Effects

• Respiratory depression: potentially life‑threatening reduction in breathing rate.
• Severe hypotension: marked drop in blood pressure, especially with rapid dose escalation.
• Opioid dependence or addiction: risk of misuse with prolonged therapy.
• Anaphylaxis: rare allergic reaction with rash, swelling, and airway compromise.
• adrenal insufficiency: uncommon endocrine disturbance with chronic high‑dose use.

Ms Contin requires careful clinical oversight to balance analgesia with safety.

• Dose titration: adjust dose individually to achieve analgesia while minimizing adverse effects.
• Respiratory depression risk: monitor patients with compromised ventilation, especially during initiation.
• Constipation: implement prophylactic laxative regimen to prevent bowel obstruction.
• Potential for dependence: assess risk factors before initiating therapy and educate patients.
• Drug interactions: review concomitant CNS depressants and adjust therapy as needed.
• Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Ms Contin may interact with several medication classes, requiring vigilance.

Major Interactions (Avoid)

• Concomitant use with other opioids or strong CNS depressants: may cause profound respiratory depression.
• MAO inhibitors: risk of severe opioid toxicity and hypertensive crisis.

Moderate Interactions (Monitor Closely)

• Benzodiazepines: increase sedation and respiratory depression; monitor closely.
• Anticholinergics: may exacerbate constipation; consider bowel regimen.
• SSRIs or SNRIs: potential for serotonin syndrome; observe for signs of agitation or hyperthermia.